The probucol-loaded CFP nanoassembly exhibited superior ROS-scavenging and anti-inflammatory effects compared to both the CF nanozyme and probucol, attributed to the synergy of the nanozyme and the drug, thus facilitating a highly efficient treatment of atherosclerosis. The gene discussed is CFP; the disease is atherosclerosis.